TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9706945

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TD-NICO) 21 mg/d for at least 10 h before anesthesia
Number of subjects: 130

Group type: COMPARATOR
Intervention: Abstinent group (ABST) with placebo transdermal system
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Smokers (SMOK) allowed to smoke until 1-3 h before anesthesia
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Nonsmokers (NON-SMOK)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TD-NICO)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Smokers (SMOK)
Number of subjects: 130
Study: 7621689

Group type: EXPERIMENTAL
Intervention: Soft jelly capsules containing nonoxynol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Storage and temperature conditions
Number of subjects: 40
Study: 2634032

Group type: EXPERIMENTAL
Intervention: Peer-led education
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Teacher-led education
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study: 330289

Group type: EXPERIMENTAL
Intervention: Acetylcysteine-isoproterenol (AI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline-isoproterenol (SI)
Number of subjects: 0
Study: 29080078

Group type: EXPERIMENTAL
Intervention: 3D xenogeneic collagen matrix (CMX)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 8
Study: 27711974

Group type: EXPERIMENTAL
Intervention: Detectable ctDNA 3 months after HSCT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Detectable ctDNA
Number of subjects: 88
Study: 24018349

Group type: EXPERIMENTAL
Intervention: Plyometric training (9-week program)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 22917265

Group type: EXPERIMENTAL
Intervention: Click version of the abdominal exam module
Number of subjects: 143

Group type: COMPARATOR
Intervention: Watch version of the abdominal exam module
Number of subjects: 143

Group type: COMPARATOR
Intervention: Drag version of the abdominal exam module
Number of subjects: 143
Study: 20028833

Group type: EXPERIMENTAL
Intervention: 12-week cognitive behavior therapy program for hostility reduction
Number of subjects: 158

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 158
Study: 19244932

Group type: EXPERIMENTAL
Intervention: Creatine (21 g) with glucose polymer (252 g) for 5 days (CR‐GP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo with glucose polymer (252 g) for 5 days (PL‐GP)
Number of subjects: 20
Study: 15990747

Group type: EXPERIMENTAL
Intervention: Rate-control therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rhythm-control therapy
Number of subjects: 0
Study: 12950123

Group type: EXPERIMENTAL
Intervention: Oral tegafur-uracil plus folinic acid (UFT group)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil plus folinic acid (5-FU group)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 10904241

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 40-120 mg
Number of subjects: 0
Study: 8738587

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-molecular-weight heparin (LMW heparin)
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Standard heparin (UF heparin)
Number of subjects: 1688
Study: 1548522

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (n = 160)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: HER‐2/neu-positive tumors (subset of low-risk lesions without significant in situ component, n = 179)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: HER‐2/neu-negative tumors (subset of low-risk lesions without significant in situ component, n = 179)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Combined low-risk and high-risk patients not receiving adjuvant therapy (n = 453)
Number of subjects: 613
Study: 2993750

Group type: EXPERIMENTAL
Intervention: Medication only
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Active support
Number of subjects: 174

Group type: COMPARATOR
Intervention: Untreated medical monitoring
Number of subjects: 174
Study: 28921862

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg once-daily
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg once-daily
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (both doses)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 464
Study: 27794093

Group type: EXPERIMENTAL
Intervention: PCVA (Physician-Certified Verbal Autopsy)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: InterVA-4 (software for verbal autopsy)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Comparison of PCVA and InterVA-4
Number of subjects: 137
Study: 25015027

Group type: EXPERIMENTAL
Intervention: MPH-LA 40 mg/day
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: MPH-LA 60 mg/day
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: MPH-LA 80 mg/day
Number of subjects: 489
Study: 23129008

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 150 × 10^6 BMCs
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BMCs at day 3
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BMCs at day 7
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BMCs
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 120
Study: 20337639

Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells injected via the noninfarct-relative artery (right coronary artery, RCA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells injected via the infarct-relative artery (left anterior descending branch artery, LAD)
Number of subjects: 16
Study: 18270353

Group type: EXPERIMENTAL
Intervention: Moderate PEEP strategy (5-9 cm H(2)O); n = 382
Number of subjects: 767

Group type: COMPARATOR
Intervention: Increased recruitment strategy (PEEP set to reach plateau pressure of 28 to 30 cm H(2)O); n = 385
Number of subjects: 767
Study: 15928685

Group type: EXPERIMENTAL
Intervention: Fortified pasteurised milk (200 µg folic acid)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Fortified pasteurised milk
Number of subjects: 69
Study: 12721666

Group type: EXPERIMENTAL
Intervention: Celecoxib (maximum single dose 200 mg, cumulative daily dose 350 mg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 10533347

Group type: EXPERIMENTAL
Intervention: Asthma management program intervention
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1635
Study: 8690116

Group type: EXPERIMENTAL
Intervention: GnRH-a and recombinant FSH
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: GnRH-a and urinary FSH
Number of subjects: 171
Study: 2069238

Group type: EXPERIMENTAL
Intervention: Preoxygenation for three minutes prior to thiopentone induction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Room air prior to induction
Number of subjects: 100
Study: 6312461

Group type: EXPERIMENTAL
Intervention: pivmecillinam plus pivampicillin (100 mg pivmecillinam plus 125 mg pivampicillin 3-times daily for 7 to 14 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: pivampicillin alone (250 mg pivampicillin 3-times daily for 7 to 14 days)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: pivmecillinam plus pivampicillin
Number of subjects: 62

Group type: COMPARATOR
Intervention: pivampicillin alone
Number of subjects: 62
Study: 30895515

Group type: EXPERIMENTAL
Intervention: StatStrip point‐of‐care test (POCT) glucose monitor
Number of subjects: 121

Group type: COMPARATOR
Intervention: GEM® Premier™ 3000 blood gas analyzer
Number of subjects: 121
Study: 29745006

Group type: EXPERIMENTAL
Intervention: 30 min of intradialytic exercise (IDEX) in the first hour of treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 min of intradialytic exercise (IDEX) in the third hour of treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 12
Study: 26892910

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 754

Group type: COMPARATOR
Intervention: Refusal of Nicotine Replacement Therapy (NRT)
Number of subjects: 754
Study: 24669988

Group type: EXPERIMENTAL
Intervention: Physical Exercise Promotion program (PEP-1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Information leaflet (control)
Number of subjects: 48
Study: 22611182

Group type: EXPERIMENTAL
Intervention: Endoscopic saphenous vein harvesting (EVH)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standard bridging technique (SBT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 150
Study: 20851230

Group type: EXPERIMENTAL
Intervention: 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate (CMA)
Number of subjects: 59
Study: 17437655

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% 10 mL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (saline 0.9%)
Number of subjects: 50
Study: 15809943

Group type: EXPERIMENTAL
Intervention: Computer-navigated total knee arthroplasty
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 52
Study: 11983194

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol E (50 I.U./day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 9708526

Group type: EXPERIMENTAL
Intervention: Cisapride (5 mg, 3 times/day, before meals, for 2 weeks)
Number of subjects: 55
Study: 7617541

Group type: EXPERIMENTAL
Intervention: Single-dose terodiline (12.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-dose terodiline (25 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multiple-dose terodiline (12.5 mg b.i.d. for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multiple-dose terodiline (25 mg b.i.d. for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall terodiline treatment
Number of subjects: 20
Study: 1322427

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6327190

Group type: EXPERIMENTAL
Intervention: Veralipride 100 mg per day for 20 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conjugated oestrogens 1.25 mg per day for 20 days
Number of subjects: 43
Study: 30193074

Group type: EXPERIMENTAL
Intervention: Basketball-specific high-intensity interval training (HIIT), 10 sessions over 5 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG), continued normal team training routine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Basketball-specific HIIT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study: 28678622

Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate mouth rinse (RCHO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo solution (RP)
Number of subjects: 15
Study: 27198036

Group type: EXPERIMENTAL
Intervention: Vitamin D (5µg), Vitamin K (90µg), Calcium (500mg)
Number of subjects: 66
Study: 24698174

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for older adults in rehabilitation after stroke
Number of subjects: 99
Study: 22855310

Group type: EXPERIMENTAL
Intervention: BIOPATCH applied to the catheter exit site
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-BIOPATCH (no patch applied)
Number of subjects: 100
Study: 19898245

Group type: EXPERIMENTAL
Intervention: Fluoxetine-clonazepam cotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fluoxetine monotherapy
Number of subjects: 80
Study: 17921424

Group type: EXPERIMENTAL
Intervention: Education program consisting of two 4-hour classroom and two 1-hour on-road sessions focused on common problem areas of older drivers.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Modules directed at vehicle, home, and environmental safety (Control).
Number of subjects: 126
Study: 16291843

Group type: EXPERIMENTAL
Intervention: Low-Dye taping for 3 to 5 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no taping)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Low-Dye taping
Number of subjects: 105
Study: 12118025

Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel (AT) regimen (doxorubicin 60 mg/m² IV bolus + paclitaxel 175 mg/m² 3-hour infusion)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide (AC) regimen (doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m²)
Number of subjects: 275
Study: 9097275

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for 6 months (Group I)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for 12 months (Group II)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for both groups
Number of subjects: 38
Study: 8126635

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g i.v. single dose)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Cefoxitin (1 g i.v. three doses)
Number of subjects: 1052
Study: 2956228

Group type: EXPERIMENTAL
Intervention: Teicoplanin+amikacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vancomycin+amikacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amikacin alone
Number of subjects: 10
Study: 31499010

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 28
Study: 29568749

Group type: EXPERIMENTAL
Intervention: Plyometric exercise (PLY)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Heavy‐resistance exercise (RES)
Number of subjects: 14
Study: 26384466

Group type: EXPERIMENTAL
Intervention: Low-Fat Dietary Pattern Intervention
Number of subjects: 48835
Study: 23880900

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 109

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 109
Study: 22963751

Group type: EXPERIMENTAL
Intervention: GLM-enriched diet
Number of subjects: 23
Study: 19756029

Group type: EXPERIMENTAL
Intervention: B‐GOS (galacto‐oligosaccharide mixture)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 159
Study: 18216374

Group type: EXPERIMENTAL
Intervention: Integrated Herbst appliance (IHA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated age-matched males with Class II malocclusions)
Number of subjects: 30
Study: 16549839

Group type: EXPERIMENTAL
Intervention: Bevacizumab infusion (VEGF antibody blockade)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD146+ cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD146 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue analysis
Number of subjects: 0
Study: 14680844

Group type: EXPERIMENTAL
Intervention: mtDNA variant at 16,189
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: mtDNA abnormalities at 3243, 3316, and 15,927
Number of subjects: 268
Study: 10720792

Group type: EXPERIMENTAL
Intervention: S. asper leaf extract
Number of subjects: 30

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 30
Study: 8788485

Group type: EXPERIMENTAL
Intervention: MDMA 0.25 to 1.0 mg/kg, p.o.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MDMA 0.5 to 0.75 mg/kg, p.o.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MDMA higher doses (above 0.75 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 6
Study: 1555550

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Codeine 50 mg
Number of subjects: 6
Study: 3884806

Group type: EXPERIMENTAL
Intervention: Piroxicam, 20 mg OD
Number of subjects: 145

Group type: COMPARATOR
Intervention: Enteric coated acetylsalicylic acid (EC ASA), 3.9‐5.2 g daily in divided doses
Number of subjects: 145
Study: 31855907

Group type: EXPERIMENTAL
Intervention: Oral 3% hypertonic saline (HTS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IV 3% hypertonic saline (HTS)
Number of subjects: 20
Study: 29966211

Group type: EXPERIMENTAL
Intervention: Fast squat exercise
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fast squat on unstable surface
Number of subjects: 38
Study: 26628478

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250mg daily plus CapeOx
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo plus CapeOx
Number of subjects: 545
Study: 24878676

Group type: EXPERIMENTAL
Intervention: BPT plus ongoing routine clinical care (RCC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: RCC alone
Number of subjects: 83
Study: 22943229

Group type: EXPERIMENTAL
Intervention: Floseal()
Number of subjects: 42
Study: 20100188

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 48
Study: 18818415

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15799733

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Retrobulbar anaesthesia
Number of subjects: 32
Study: 12410785

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 295
Study: 10430526

Group type: EXPERIMENTAL
Intervention: Gelseal prostheses
Number of subjects: 25

Group type: COMPARATOR
Intervention: Gelweave prostheses
Number of subjects: 25
Study: 7588502

Group type: EXPERIMENTAL
Intervention: oat gum instant whip, 9 g beta‐glucan/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo instant whip
Number of subjects: 14
Study: 1688970

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine (N)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study: 634316

Group type: EXPERIMENTAL
Intervention: Nitroprusside plus hydroxocobalamin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroprusside alone
Number of subjects: 0
Study: 31486694

Group type: EXPERIMENTAL
Intervention: Topical triamcinolone acetonide‐loaded liposomal formulation (TA‐LF) 2 mg/mL (0.2%) for 21 days postoperatively
Number of subjects: 56

Group type: COMPARATOR
Intervention: Combined therapy with prednisolone 1% and nepafenac 0.1% for 21 days postoperatively
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Topical triamcinolone acetonide‐loaded liposomal formulation (TA‐LF)
Number of subjects: 56
Study: 28276950

Group type: EXPERIMENTAL
Intervention: Spiritual care therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no spiritual care)
Number of subjects: 0
Study: 26231885

Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril-valsartan)
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study: 23382191

Group type: EXPERIMENTAL
Intervention: Metreleptin administration
Number of subjects: 0
Study: 20883582

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 536

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 536
Study: 19019768

Group type: EXPERIMENTAL
Intervention: Methylene blue-stained group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unstained group
Number of subjects: 60
Study: 15919229

Group type: EXPERIMENTAL
Intervention: Cervical joint position error (JPE)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Smooth pursuit neck torsion test (SPNT)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Rotation cervical JPE score
Number of subjects: 140
Study: 12505557

Group type: EXPERIMENTAL
Intervention: Compliant use of CPAP at 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Noncompliant use of CPAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline attention measures
Number of subjects: 12
Study: 10758695

Group type: EXPERIMENTAL
Intervention: Theophylline (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Beclomethasone (group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Salbutamol (group C)
Number of subjects: 45
Study: 8899080

Group type: EXPERIMENTAL
Intervention: Butyrate enemas (60 mL of 80 mM sodium butyrate)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline/placebo enemas
Number of subjects: 38
Study: 1799912

Group type: EXPERIMENTAL
Intervention: Cefotaxime 500 mg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg
Number of subjects: 142
Study: 6351363

Group type: EXPERIMENTAL
Intervention: TCu 220C
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Lippes Loop D
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Copper 7
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Control (immediate insertion after delivery of placenta)
Number of subjects: 1060
Study: 29358531

Group type: EXPERIMENTAL
Intervention: Simple child meal (SCM; n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hearty child meal (HCM; n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups (SCM and HCM)
Number of subjects: 16
Study: 27023901

Group type: EXPERIMENTAL
Intervention: Early-sitting group (seated out of bed within one calendar day after stroke onset)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Progressively-sitting group (seated out of bed on the third calendar day after stroke onset)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Early-sitting group
Number of subjects: 138

Group type: COMPARATOR
Intervention: Progressively-sitting group
Number of subjects: 138
Study: 23364318

Group type: EXPERIMENTAL
Intervention: Internet-based AOM Family Intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Workbook-based AOM Family Intervention
Number of subjects: 131
Study: 24349257

Group type: EXPERIMENTAL
Intervention: Game-based e-learning (GbEl)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional script-based instruction (script group)
Number of subjects: 145